Key Takeaways Rapid adoption of advanced platforms and strong momentum in underserved regions position Elekta for outsized revenue growth and improved profit margins. Leadership in precision radiotherapy technologies and digital health creates high-margin, recurring revenues and raises barriers to entry for competitors.Read more
Key Takeaways Successful software launches and service expansion are boosting sales growth, margins, and predictable cash flow, especially as global adoption of precision radiotherapy accelerates. Market recovery in China and emerging regions, supported by cost control and strong cancer treatment demand, positions Elekta for sustained earnings and multi-year revenue growth.Read more
Key Takeaways Rising global trade barriers, reimbursement pressures, and aggressive competition are constraining margins, threatening earnings predictability, and slowing potential revenue growth across Elekta's markets. Underinvestment in R&D and operational challenges in emerging markets are eroding Elekta's technological edge and compressing both current and future profitability.Read more
Excellent balance sheet with reasonable growth potential and pays a dividend.
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear accelerator and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo that delivers offline and online adaptive radiation therapy; Elekta Versa HD, a brain metastases solution; Elekta Harmony; and Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs, as well as quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit, a gamma knife system; and Leksell GammaPlan, a treatment planning and management software, as well as Elekta ONE, an oncology software suite. In addition, the company offers brachytherapy products, including Elekta Studio, an image-guided brachytherapy solution; ImagingRing for dynamic imaging; Oncentra Brachy, a smart tool that facilitates repetitive tasks; Elekta Xoft Axxent and electronic brachytherapy systems; Elekta Geneva, an applicator for cervical cancer patients; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Venezia applicator that enables the oncologist to treat locally advanced cervical cancer. Further, it provides Leksell Vantage Stereotactic System, a neurosurgery product; Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. Additionally, the company offers Elekta Care support services; Elekta Care 360, which provides a range of clinical and professional services; Elekta Care Learning that offers in-person and digital training courses on radiotherapy; Elekta Care Community, a self-help center; Elekta Partner Community, an online self-service portal; and Elekta Intellimax for predictive maintenance. Elekta AB (publ) was incorporated in 1972 and is headquartered in Stockholm, Sweden.
